Glofitamab Combined With Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

Assess the efficacy and safety of glofitamab in combination with selinexor for the treatment of relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL) in patients who have received at least two prior lines of systemic therapy.

Inclusion Criteria: * Age 18 years and older at the time of informed consent. * Histologically confirmed CD20+ diffuse large B-cell lymphoma (DLBCL). * Relapsed or refractory disease, having previously received at least two lines of systemic therapy. * Eastern Cooperative Oncology Group (ECOG) performance status score of 0, 1, or 2. * Presence of measurable disease. * Adequate hematologic, hepatic, and renal function. * Willingness to use effective contraception methods during the study and for a specified period after the last dose. * Willing and able to provide written informed consent and comply with the study protocol. Exclusion Criteria: * Prior treatment with any CD20/CD3 bispecific antibodies or XPO1 inhibitors. * Current or prior history of central nervous system (CNS) involvement by lymphoma or other significant CNS diseases. * Active and uncontrolled systemic infections, including known HIV infection, active Hepatitis B virus (HBV), or active Hepatitis C virus (HCV) infection. * Active autoimmune diseases requiring systemic immunosuppressive therapy. * Clinically significant, severe, or uncontrolled cardiovascular diseases. * Other active invasive malignancies within the past 2 years (with exceptions for adequately treated localized cancers). * Recent major surgery or receipt of live attenuated vaccines within a specified timeframe prior to the study. * Severe gastrointestinal conditions that may significantly affect the absorption of oral medications. * Known severe allergic reactions to any of the study drugs or their excipients. * Pregnant or breastfeeding women.